Rare Disease Platform SmartPharm leverages a next generation non-viral gene therapy platform targeting rare diseases, including lysosomal storage disorders, offering opportunities for co-development or licensing with biopharma seeking differentiated gene therapy capabilities.

Defense Collaboration Past DARPA engagement and rapid countermeasure development suggest readiness to engage with government programs on fast tracked therapeutics, offering a potential path for government funded partnerships or contract manufacturing for defense biosurveillance and response programs.

Backed by Sorrento As a subsidiary of Sorrento Therapeutics, SmartPharm benefits from integration into a larger corporate framework, potentially enabling co development, shared IP, and access to expanded funding, manufacturing, and commercialization channels.

Early Stage Funding With modest revenue and early stage funding, opportunities exist for milestone driven collaborations, grant funded programs, and shared risk partnerships with pharma seeking innovative preclinical platforms to de-risk early development.

Cambridge Access Located in Cambridge, MA, the company sits in a dense biotech hub with proximity to universities, CROs, and potential collaborators, enabling strategy to pursue joint research, academic partnerships, and access to specialized talent and manufacturing partners for gene therapy programs.